Orphan designation: N-((R)-2,3-dihydroxypropoxyl)-3,4-difluro-2-(2-fluoro-4-iodo-phenylamino)-benzamide Treatment of neurofibromatosis type 1, 25/07/2019 Positive

Orphan designation: N-((R)-2,3-dihydroxypropoxyl)-3,4-difluro-2-(2-fluoro-4-iodo-phenylamino)-benzamide Treatment of neurofibromatosis type 1, 25/07/2019 Positive

Metadata
Provider: 
European Medicines AgencyEuropean Medicines Agency
URL: 
https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2184https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-19-2184
Retrieved on: 
Thursday, April 18, 2024
Information
Tags: 
Eurostat, Diagnosis, Civil service commission, Optic nerve, Brain, Enzyme, Growth, Cell, NF1, Disease, Nervous system, Risk, Groin, Patient, Committee, Knowledge, Neoplasm, Regulation, Cancer, EMA, IRIS, Eye, European, Therapy, COMP, Safety, European Commission, Marketing, Medicine, Pharmaceutical industry
Geotags: 
EUROPEAN UNION, RARE, EC, ICELAND, EU, FRANCE, NORWAY, UNITED STATES, LIECHTENSTEIN
Summary
Key Points: 


Orphan designation: N-((R)-2,3-dihydroxypropoxyl)-3,4-difluro-2-(2-fluoro-4-iodo-phenylamino)-benzamide Treatment of neurofibromatosis type 1, 25/07/2019 Positive

Copyright: 
2024 European Medicines Agency. All Rights Reserved.